Title |
Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS)
|
---|---|
Published in |
Journal of Clinical Immunology, October 2015
|
DOI | 10.1007/s10875-015-0203-z |
Pubmed ID | |
Authors |
Seiji Yokoyama, Pin-Yu Perera, Seigo Terawaki, Nobumasa Watanabe, Osamu Kaminuma, Thomas A. Waldmann, Takachika Hiroi, Liyanage P. Perera |
Abstract |
Autoimmune lymphoproliferative syndrome (ALPS) is a non-malignant genetic disorder of lymphocyte homeostasis with defective Fas-mediated apoptosis. Current therapies for ALPS primarily target autoimmune manifestations with non-specific immune suppressants with variable success thus highlighting the need for better therapeutics for this disorder. The spectrum of clinical manifestations of ALPS is mirrored by MRL/lpr mice that carry a loss of function mutation in the Fas gene and have proven to be a valuable model in predicting the efficacy of several therapeutics that are front-line modalities for the treatment of ALPS. We evaluated the potential efficacy of tofacitinib, an orally active, pan-JAK inhibitor currently approved for rheumatoid arthritis as a single agent modality against ALPS using MRL/lpr mice. We demonstrate that a 42-day course of tofacitinib therapy leads to a lasting reversal of lymphadenopathy and autoimmune manifestations in the treated MRL/lpr mice, Specifically, in treated mice the peripheral blood white blood cell counts were reversed to near normal levels with almost a 50 % reduction in the TCRαβ(+)CD4(-)CD8(-)T lymphocyte numbers that coincided with a parallel increase in CD8(+) T cells without a demonstrable effect on CD4(+) lymphocytes including FoxP3(+) regulatory T cells. The elevated plasma IgG and IgA levels were also drastically lowered along with a significant reduction in plasmablasts and plasmacytes in the spleen. On the basis of these results, it is likely that tofacitinib would prove to be a potent single agent therapeutic modality capable of ameliorating both offending lymphadenopathy as well as autoimmunity in ALPS patients. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 3% |
Unknown | 28 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Unspecified | 10 | 34% |
Other | 4 | 14% |
Researcher | 4 | 14% |
Student > Bachelor | 2 | 7% |
Student > Doctoral Student | 2 | 7% |
Other | 3 | 10% |
Unknown | 4 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Unspecified | 10 | 34% |
Medicine and Dentistry | 7 | 24% |
Agricultural and Biological Sciences | 3 | 10% |
Biochemistry, Genetics and Molecular Biology | 2 | 7% |
Immunology and Microbiology | 1 | 3% |
Other | 2 | 7% |
Unknown | 4 | 14% |